Expert Interviews
Expert Interviews
Advertisement
Cecilia BrownLung Cancer | May 15, 2025
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
View More
Michael R. Gieske, MDLung Cancer | May 9, 2025
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Stephen V. Liu, MDLung Cancer | May 9, 2025
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Alexander Spira, MD, PhDELCC 2025 | May 8, 2025
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Mara B. Antonoff, MD, FACSLung Cancer | May 6, 2025
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
Jared Weiss, MDELCC 2025 | May 2, 2025
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Mara B. Antonoff, MD, FACSLung Cancer | April 30, 2025
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
Stephen V. Liu, MDEGFR+ NSCLC | April 24, 2025
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhDELCC 2025 | April 16, 2025
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Martin Reck, MD, PhDELCC 2025 | April 12, 2025
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
Martin Reck, MD, PhDELCC 2025 | April 9, 2025
Martin Reck, MD, PhD, reflects on key updates in stage III NSCLC from the European Lung Cancer Congress 2025.
Stephen V. Liu, MDImmunotherapy in NSCLC | April 7, 2025
Stephen V. Liu, MD, weighs in on the data from the preplanned interim analysis that was recently published in The Lancet.
Nicolas Girard, MD, PhDELCC 2025 | March 27, 2025
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Stephen V. Liu, MDELCC 2025 | March 24, 2025
Dr. Liu shares what he's looking forward to during the European Lung Cancer Congress, which will be held March 26-29.
Wui-Jin Koh, MDConference Coverage | March 19, 2025
The NCCN 2025 Annual Conference will be held from March 28-30 in Orlando, Florida.
Mara B. Antonoff, MD, FACSLung Cancer | March 12, 2025
Mara B. Antonoff, MD, FACS, discusses the organization's mission, the resources it offers, and her hopes for the future.
Stephen V. Liu, MDNon-Small Cell Lung Cancer | March 7, 2025
Dr. Liu unpacks key questions in the field, and the research that could address them.
Jorge Nieva, MDWCLC 2024 | February 24, 2025
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Stephen V. Liu, MDNon-Small Cell Lung Cancer | February 20, 2025
Dr. Liu unpacks the trial results, the recent approval, and the unique biomarker testing considerations for NRG1 fusions.
Christopher Seder, MDSTS 2025 | February 14, 2025
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
Advertisement
Advertisement
Latest News

May 19, 2025